Establishes IGT as a Premier Platform for Innovation, Delivering Exceptional Content and Scalable Solutions Across the Global Gaming EcosystemNEW YORK and LAS VEGAS, July 01, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced the completion of the previously announced acquisitions of International Game Technology PLC’s (doing business as “Brightstar Lottery”) Gaming & Digital Business and Everi Holdings Inc. ("Everi") by a holding company owned by funds managed by Apollo affiliates (the "Apollo Fun ...

Core Points - TuHURA Biosciences, Inc. has been added to the Russell 3000® Index and automatically included in the Russell 2000® Index as part of the 2025 annual reconstitution, effective June 27, 2025 [1][2] - The inclusion in the Russell indexes signifies the company's progress in its first year as a publicly traded entity and reflects its potential for continued development [2] - TuHURA is currently enrolling patients in a Phase 3 accelerated approval trial of its lead product IFx-2.0, which is being tested as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel cell carcinoma [2][11] - The company has also acquired a novel anti-VISTA antibody from Kineta, Inc. and plans to advance it into a Phase 2 clinical trial for treating NMPL1-mutated Acute Myeloid Leukemia [2] Company Overview - TuHURA Biosciences, Inc. is focused on developing novel technologies to overcome resistance to cancer immunotherapy, addressing both primary and acquired resistance [10] - The company's lead product, IFx-2.0, is designed to enhance the effectiveness of checkpoint inhibitors [11] - TuHURA is also leveraging its Delta Opioid Receptor technology to create bi-specific antibody drug conjugates aimed at inhibiting immune suppression in the tumor microenvironment [12]

Core Insights - The National Healthcare Security Administration (NHSA) introduced measures to support the high-quality development of innovative drugs, encouraging commercial health insurance to expand investment in innovative drugs and create a directory for innovative drugs [1][2] Group 1: Policy Impact - The new policies provide clear direction for the development of commercial health insurance, which is crucial for establishing a multi-tiered medical payment system in China [1] - The introduction of a commercial health insurance directory for innovative drugs aims to include drugs with high innovation, significant clinical value, and benefits that exceed basic medical insurance coverage [2] Group 2: Market Dynamics - The innovative drug payment market is on the verge of explosive growth, with expectations of a layered payment ecosystem emerging over the next five years [1][2] - Companies like Mingxin Health are positioning themselves to address payment challenges in the industry, having become the largest multi-payment platform in China since its establishment in 2017 [3] Group 3: Financial Performance - Mingxin Health reported significant revenue growth, with revenues of 1.069 billion, 1.255 billion, and 2.035 billion yuan from 2022 to 2024, reflecting a compound annual growth rate of approximately 38% [3] Group 4: Future Business Models - Potential business models include creating data bridges between medical services, insurance, and commercial health insurance, as well as designing performance-based agreements and customized insurance products [4] - Companies aim to resolve structural conflicts between payment and supply sides to achieve a sustainable ecosystem where patients have access to affordable medical products [4]

GTC泽汇表示，自6月5日以来，Circle股价飙涨750%，成为近期加密市场最引人注目的现象。这波暴涨 不仅凸显投资者对稳定币赛道的高度关注，也反映出传统金融资本加速涌入数字资产领域的趋势。但在 投资热情背后，投机情绪、市场波动和监管风险仍构成潜在挑战。 GTC泽汇表示，Sei上周涨幅高达40.19%，成为表现最佳的加密资产之一。同时，由Tether联合创始人和 前黑石交易员发起的一家新加密资产公司，正在筹资10亿美元，投资范围覆盖比特币、以太坊和Solana 等主流资产，标志着专业机构正在大举进场。 Circle股价的大幅拉升，反映出市场对稳定币业务未来增长的强烈预期。GTC泽汇认为，随着稳定币监 管体系逐步清晰，金融机构正积极探索发行与应用场景，稳定币正从加密世界边缘资产，迈向数字金融 核心基础设施的角色。 与此同时，比特币一度跌破10万美元关口，引发市场恐慌。此次波动与特朗普宣布对伊朗三大核设施实 施打击有关，突显地缘政治对市场的高度影响。以太坊同步大跌10%，创下近两个月新低，24小时内加 密市场总清算额超过10亿美元。 GTC泽汇警示，当前部分项目估值泡沫明显，商业逻辑尚不成熟，投资者需警惕此类" ...

此次竞拍成功，原本通过东莞金控资本投资有限公司（下称"金控资本"）、东莞控股、东莞金控间接控 制东莞证券55.4%股份的东莞市国资委所持股权将进一步增加20%。 此前东莞控股解释为何竞拍东莞证券股权时称，与后者的经营状况以及IPO进程有关，"近年来，东莞 证券经营情况稳定，近三年证券公司分类评价均被评为A类A级，申报IPO正在审核阶段，具有一定投 资价值。" 本次交易总交易价款为22.72亿元，东莞金控和东莞控股已按《股份转让协议》约定支付了全部转让价 款。标的资产过户手续已办理完毕。 截至评估基准日2023年年底，按照市场法评估东莞证券全部权益的评估值为113.9亿元，增值率为 24.98%。挂牌的参考底价为22.72亿元。本次交易为底价成交。 锦龙股份（000712）7月1日晚间公告，公司已通过上海联合产权交易所公开挂牌转让所持有的东莞证券 3亿股股份(占东莞证券总股本的20%)。本次交易完成后，锦龙股份仍持有东莞证券3亿股股份(占东莞证 券总股本的20%)。 东莞证券多年前就试图IPO，但一直未能成功。 根据公开挂牌结果，本次交易对方为东莞金控和东莞控股（000828），其中东莞金控受让1.94亿股(占 ...

PICC Group 601319.SH PICC Group 1339.HK PICC P&C 2328.HK The information contained herein includes certain forward-looking statements or statements which are potentially of a forward-looking nature. Such statements typically contain the words "will", "expects", "anticipates", and similar expressions. Forward-looking statements are related to future events and are subject to future happenings, and hence involving risks and uncertainties. Given these uncertainties, such forward-looking statements should not b ...

数字经济、高技术产业、机器人产业三个领域共减免企业所得税1.97万亿元，总营业收入同比增长 7.1%，利润总额同比增长5.2%……今年5月底结束的2024年度企业所得税汇算清缴数据显示，去年以来 一系列支持科技创新的税收优惠政策落实落细，政策红利精准快速直达经营主体，支持三个行业发展向 新向好。 今年以来，在宏观政策发力显效和产业升级等的带动下，我国经济展现出较强韧性和增长潜力，以数字 经济、高技术产业、机器人产业为代表的新质生产力加快培育和发展，为经济高质量发展蓄势赋能。 数字经济融合渗透不断加大，对工业生产带动作用增强。国家统计局发布的数据显示，5月份数字产品 制造业增加值增长9.1%，明显高于全部规模以上工业增速。1至5月份，规模以上数字产品制造业增加 值同比增长9.9%。 高技术产业"上天入地"尽显活力 今年以来，我国经济新旧动能逐步转换，创新驱动发展作用不断增强，高技术产业发展向好。税收数据 显示，2024年度，医药制造、航空航天等高技术产业营业收入和利润总额同比分别增长8.9%、7.5%。 从细分行业看，科学研究和技术服务业营业收入和利润总额同比分别增长11.7%、7.5%，航空航天产业 营业收入 ...

近两周，国际金价持续震荡，伦敦金现、COMEX黄金均下跌超3%。与此同时，港股老铺黄金却逆市累计涨超6%，股价也创下新高。消息面上， 老铺黄金近日在上海开设新门店，海外首店也落子新加坡。另外，从重仓老铺黄金的基金上半年收益率来看，个别产品大涨近50%且在同类基金 中排名靠前。不过，也有业内人士提醒，现阶段追高黄金仍需谨慎，在历史高位区域追高黄金，需要考虑黄金属于不生息资产，一旦黄金价格发 生实质性的价格拐点，可能会增加时间成本与持有风险。 公开资料显示，老铺黄金创立于2009年。2020年，老铺黄金曾闯关A股IPO，计划在深交所上市，最终被否。2022年，老铺黄金再度冲击深交所， 但在2023年7月主动撤回IPO申请。2024年6月28日，老铺黄金成功在港交所挂牌。自登陆港股市场以来，老铺黄金股价波动上升且屡创新高，目 前其股价已较发行价40.5港元/股涨超23倍。 老铺黄金股价创新高 下半年首日，国际金价走势上扬。交易行情数据显示，7月1日，伦敦金现、COMEX黄金价格均重回3330美元/盎司。截至17时，伦敦金现、 COMEX黄金报3338.75美元/盎司、3350.6美元/盎司，涨1.1%、1.31%。 ...

Core Viewpoint - The A-share listed companies have shown positive performance in their half-year reports, with a significant proportion of companies expecting profit growth, driven by various factors including international market expansion and cost reduction measures [1][2][3]. Group 1: Performance Forecasts - Out of 26 companies that announced their performance forecasts, approximately 77% are expected to report positive results, with 9 companies anticipating "slight growth," 6 "increased growth," 4 "continued profit," 1 "turning profitable," and 1 "slight decrease" [2][3]. - Companies such as Guangda Special Materials and Shengnuo Bio are expected to see net profit increases exceeding 100% [2][5]. - The industries with the highest concentration of companies expecting positive results include pharmaceuticals, semiconductors, and hardware equipment [2][9]. Group 2: Individual Company Highlights - Guangda Special Materials forecasts a net profit of approximately 200 million yuan, representing a growth of 367.51% [4][5]. - Shengnuo Bio anticipates a net profit between 77.03 million and 94.14 million yuan, with a growth rate of 253.54% to 332.10% [4][5]. - Tai Ling Micro expects a net profit of about 99 million yuan, reflecting a growth of approximately 267% [4][6]. Group 3: Market Trends and Insights - The overall net profit growth of A-share listed companies is expected to continue improving, driven by macroeconomic policies and industry restructuring [8][9]. - Analysts predict that sectors such as consumer services, information technology, and midstream manufacturing will see relatively high profit growth in 2025 [8][9]. - The market sentiment is optimistic, with many institutions recommending an overweight position in the Chinese stock market, anticipating a bull market in both A-shares and Hong Kong stocks [9].

四川江油龙门山脉深处，松花岭一隅，坐落着几台高低错落的大型试验设备。有着"亚洲第一台"字样的 石刻矗立在旁，静静诉说一个甲子的峥嵘岁月。 这是我国第一座航空发动机高空模拟试车台（简称"高空台"）的诞生地。高空台，是在地面模拟航空发 动机在空中飞行时的高度、速度和进气畸变条件的试车台，是研制先进航空发动机必不可少的大型试验 设施之一。每一款新型航空发动机正式列装交付前，都需要经过高空台的试验，以确保其安全可靠为飞 机提供动力保障。 "它打破国外技术封锁，已完成近百型现役和在研发动机的鉴定和科研试验，是我们心中的'争气 台'。"近日，在中国航空发动机集团的"国企开放日"上，中国航发涡轮院专职总师刘志友的这句话掷地 有声。 这是2004年8月，在松花岭试验基地拍摄的航空发动机高空模拟试车台加温炉外景。（中国航空发动机 集团供图） 1965年，老一辈航发人带着国家期望和民族使命，从天南海北汇聚四川，在一片荒芜之地"边建设、边 研究"，不分白天黑夜，逢山凿洞、遇沟架桥，在这片"蜀道难"之地开创"上青天"的事业。 零起点、零基础、零经验。在国外严密的技术封锁下，经过30年艰苦奋斗，1995年，高空台终于建成投 用，我国一 ...